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½ maximally suppress serum non-esterified fatty acids; p <0.05),
and specifically within subcutaneous adipose tissue (p <0.05). InGlucagon-like peptide-1 (GLP-1) analogues are licensed for type
2 diabetes, but no prospective experimental data exists in NASH.
This study determined the effect of a long-acting GLP-1 analogue,
liraglutide, on organ-specific insulin sensitivity, hepatic lipid
handling and adipose dysfunction in biopsy-proven NASH.
Methods: Fourteen patients were randomised to 1.8 mg
liraglutide or placebo for 12-weeks of the mechanistic compo-
nent of a double-blind, randomised, placebo-controlled trial
(ClinicalTrials.gov-NCT01237119). Patients underwent paired
hyperinsulinaemic euglycaemic clamps, stable isotope tracers,
adipose microdialysis and serum adipocytokine/metabolic profil-
ing. In vitro isotope experiments on lipid flux were performed on
primary human hepatocytes.
Results: Liraglutide reduced BMI (1.9 vs. +0.04 kg/m2;
p <0.001), HbA1c (0.3 vs. +0.3%; p <0.01), cholesterol-LDL
(0.7 vs. +0.05 mmol/L; p <0.01), ALT (54 vs. 4.0 IU/L;
p <0.01) and serum leptin, adiponectin, and CCL-2 (all p <0.05).
Liraglutide increased hepatic insulin sensitivity (9.36 vs.
2.54% suppression of hepatic endogenous glucose production
with low-dose insulin; p <0.05). Liraglutide increased adipose tis-
sue insulin sensitivity enhancing the ability of insulin to suppress
lipolysis both globally (24.9 vs. +54.8 pmol/L insulin required toJournal of Hepatology 20
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in vivo (1.26 vs. +1.30%; p <0.05); a finding endorsed by the
effect of GLP-1 receptor agonist on primary human hepatocytes
(24.6% decrease in lipogenesis vs. untreated controls; p <0.01).
Conclusions: Liraglutide reduces metabolic dysfunction, insulin
resistance and lipotoxicity in the key metabolic organs in the
pathogenesis of NASH. Liraglutide may offer the potential for a
disease-modifying intervention in NASH.
 2016 The Authors. Published by Elsevier B.V. on behalf of the
European Association for the Study of the Liver. This is an open
access article under the CC BY license (http://creativecommons.
org/licenses/by/4.0/).Introduction
Non-alcoholic steatohepatitis (NASH) incurs a significantly
increased risk of both liver- and cardiovascular disease (CVD)-
related morbidity and mortality [1], yet, there remains a lack of
safe and efficacious pharmacological treatments [2].
Insulin resistance (IR) in both liver and adipose tissue is
believed to be a key driver in the pathogenesis of NASH [3].
Detailed metabolic studies, using ‘gold-standard’ euglycaemic
clamps and/or stable isotope tracers, have demonstrated that
patients with NASH have severe adipose IR, alongside increased
hepatic IR [4,5] and de novo lipogenesis (DNL) [6,7]. Even though
collectively these contribute to excess lipid accumulation in the
liver, it is widely believed that the overspill of non-esterified fatty
acids (NEFA) and release of triglyceride-derived toxic metabolites
from adipose tissue lipolysis, form the primary lipotoxic insult in
the pathogenesis of NASH and its extrahepatic complications
including increased CVD-morbidity and mortality [1,8]. In
addition to driving intrinsic hepatic IR and inflammation, hepatic
lipotoxicity is thought to further fuel the circulating16 vol. 64 j 399–408
Research Article
pro-inflammatory milieu and IR status in NASH, which in turn
contributes to the cycle of worsening adipose dysfunction and
lipolysis [8]. Therefore, identifying pharmaceutical options that
can target both liver and adipose IR as well as reduce hepatic
exposure to the effects of lipotoxic metabolites may provide the
best strategy to halt the progression of NASH and its clinical
consequences.
Glucagon-like peptide-1 (GLP-1) analogues have been shown to
improve glycaemic control, weight loss and in retrospective stud-
ies, liver enzymes in patients with type 2 diabetes [9], making
them an attractive therapeutic option in NASH. Recent animal
studies of NASH have supported these findings by demonstrating
improvements in hepatic steatosis following GLP-1 therapy [10–
13], which in some cases was accompanied by reductions in oxida-
tive stress [11,14,15] and fibrosis [16]. In particular, using eugly-
caemic clamp techniques, murine studies have shown that
chronic GLP-1 administration improves insulin sensitivity and
reduces hepatic glucose production [13,17,18]. Similar findings
have been reported with short-durations of GLP-1 treatment rang-
ing from single infusions up to 6-weeks in healthy volunteers [19]
and in patients with type 2 diabetes [20]. Importantly, no such
studies have been performed in the context of patients with NASH.
The effects of GLP-1 on muscle insulin sensitivity in humans have
been inconsistent albeit with most studies showing improvements
in glucose disposal [19,21,22]. To date, there are no data that
have examined the impact of GLP-1 treatment on human adipose
insulin action in vivo.
The effect of GLP-1 analogues on metabolic dysfunction, most
notably tissue-specific IR and hepatic DNL, in patients with
biopsy-confirmed NASH is currently unknown. We therefore
incorporated functional measures of lipid and carbohydrate flux
at baseline and 12 weeks into the treatment regimen of our phase
II, double-blinded, placebo-controlled randomised clinical trial,
entitled ‘Liraglutide Efficacy and Action in NASH (LEAN) [23]’.
Our aims were to determine the effect of 12-weeks treatment
of liraglutide on tissue-specific IR (adipose, muscle, liver), hepatic
DNL and adipose tissue function in patients with biopsy-defined
NASH. In addition, we performed isotope tracer studies on
primary cultures of human hepatocytes to establish if GLP-1 ana-
logues have direct lipid-lowering effects, independent of changes
in weight and glycaemic control as reported in vivo.Methods and materials
Clinical study
The full clinical protocol of the LEAN trial (clinicaltrials.gov NCT01237119) has
previously been described [23]. This was an investigator-initiated/led study, with
charitable (Wellcome Trust, NIHR) and pharmaceutical (Novo Nordisk Ltd)
support, with the University of Birmingham (UK) acting as the sole sponsor.
The National Research Ethics Service (NRES) East Midlands – Northampton com-
mittee (UK) and the Medicines and Healthcare products Regulatory Agency
(MHRA) approved all versions of the study protocol. All adult subjects gave
informed written consent prior to participation.
Study participants
Consecutive adult patients from the Queen Elizabeth University Hospital
Birmingham trial site only (UK), who met the eligibility criteria for the LEAN trial,
were given the option of participation in the current experimental metabolic
study. With the exception of the voluntary component, other aspects of study bias
were minimised by incorporating the metabolic sub-study into the first 12-weeks
of the randomised, double-blinded, placebo-controlled LEAN trial. The full eligi-
bility criteria are listed in the published trial protocol [23]. All participants had400 Journal of Hepatology 201a definitive diagnosis of NASH on liver biopsy within 6 months of the study, as
defined by two independent liver histopathologists [2]. The participants were
of adult age (18–70 years) and had a body mass index (BMI)P25 kg/m2. Patients
with co-existing type 2 diabetes were diet-controlled or were on a stable dose of
metformin ± gliclazide for a minimum of 3 months prior to the study and had a
HbA1c <9.0%. All patients with no previous diagnosis of type 2 diabetes
underwent a 75 g oral glucose tolerance test.
Treatment groups
Patients who satisfied the eligibility criteria were randomly assigned on a 1:1
basis to once-daily (OD) subcutaneous injection of 1.8 mg liraglutide (Victoza,
Novo Nordisk A/S, Denmark) or liraglutide-placebo control (Novo Nordisk A/S,
Denmark). To aid with gastrointestinal tolerability the dose was titrated by
0.6 mg every 7 days from a starting dose of 0.6 mg OD until the maximum dose
of 1.8 mg OD was achieved.
Study design
At baseline and after 12-weeks of treatment all participants underwent paired 2-
step hyperinsulinaemic euglycaemic clamps incorporating stable isotopes with
concomitant subcutaneous adipose tissue microdialysis at the NIHR/Wellcome
Trust Clinical Research Facility (WTCRF, Birmingham, UK) (Supplementary
Fig. 1). A full description of such is detailed in the Supplementary Methods.
Participants were admitted to the WTCRF the evening (17.00 hours) before
the euglycaemic clamp study. After a standardised meal, participants were
fasted until completion of the clamp study, with the exception of drinking oral
deuterated water (2H2O) to determine rates of DNL. At 08.00 hours the next
morning fasting blood samples were taken and an adipose microdialysis cathe-
ter was inserted into the abdominal subcutaneous adipose tissue (SAT), prior to
starting the 2-step hyperinsulinaemic euglycaemic clamp (as previously
described [24]). Thereafter, microdialysate samples were collected into micro-
vials (0.3 ll/min) every 30 minutes until the end of the clamp. After basal mea-
surements, hepatic and peripheral (‘muscle’) insulin sensitivity were assessed
with consecutive 2 hour infusions of insulin at 20 and 100 mU/m2/min, respec-
tively. Fasting glycaemic concentrations were maintained (‘clamped’) with a
concomitant variable infusion of 20% glucose enriched with U-[13C]-glucose
(4%) throughout the hyperinsulinaemic phases. During the 6 hour clamp, steady
state blood samples were taken at three time points in the final 30 minutes
of the basal (90–120 min), low-dose (210–240 min) and high-dose insulin
(330–360 min) phases.
Data collection and analysis
Participant demographics and clinical/biochemical measures were recorded at
baseline and after 12-weeks of treatment (see Supplementary Methods). Serum
insulin (Mercodia, Sweden), NEFA (Zen-Bio, USA) and adipocytokines (Fluo-
rokine Multi-Analyte Profiling; R&D Systems, United Kingdom) were measured
using commercially available kits, as previously described [24]. In addition,
abdominal SAT microdialysate samples were analysed using a mobile photomet-
ric, enzyme-kinetic analyser (CMA Iscus Flex, Sweden) for interstitial glycerol
concentrations.
Stable Isotope Mass Spectrometry analysis
The enrichment of U-[13C]-glucose in plasma (for hepatic endogenous glucose
production (EGP) and glucose disposal (Gd) calculations) and deuterium (2H) in
the body water pool/palmitate fraction of total plasma triglycerides (for DNL cal-
culations) were determined by gas chromatography-mass spectrometry, as previ-
ously described [24,25].Data definitions and calculations
Hepatic (hepatic EGP) and muscle (Gd) sensitivity were calculated by using mod-
ified versions of the Steele Equations. In order to quantify whole body lipolysis
and adipose tissue insulin sensitivity, the Adipose-IR index and the insulin con-
centrations causing half-maximal suppression of serum NEFA (INS ½-max NEFA)
were calculated for each participant using regression analysis [24,25]. The INS
½-max NEFA was interpolated from the gradient in decline in circulating NEFA
following the transition from basal, to low and then to high-dose insulin
(maximal suppression) across the duration of the clamp. Similarly, the rate of
glycerol release from SAT in response to fasting, low- and high-dose insulin
was used to determine abdominal SAT lipolysis and insulin sensitivity. The
percentage contribution of hepatic DNL to endogenous palmitate synthesis was
determined by the incorporation of 2H2O in the palmitate present in the plasma
total triglyceride pool, as previously described [24,25].6 vol. 64 j 399–408
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Human hepatocyte cultures
Cell culture
Cryopreserved primary human hepatocytes were purchased from Celsis IVT
Technologies (Baltimore, Maryland, USA) and cultured at 37 C in 5% CO2 using
InvitroGROTM CP medium with TorpedoTM antibiotic mix (Celcis, USA). All primary
hepatocytes were from non-obese, non-diabetic male donors, with no history of
liver disease or excess alcohol history (Supplementary Table 1). For all
experiments, cells were serum-starved prior to treatment with either
10 nM/100 nM Exendin-4 (GLP-1 analogue; Sigma) or 5 nM insulin (positive con-
trol; Sigma). HuH7 cell lines were purchased from American Type Culture Collec-
tion (Manassas, VA, USA) and cultured at 37 C in 5% CO2 using Dulbecco’s
Modification of Eagle’s Medium (DMEM) (Invitrogen, UK) with 10% foetal calf
serum (FCS) (Gibco, UK), 1% non-essential amino acids, 2 mM glutamine,
10,000 units/l Penicillin and 10 mg/ml Streptomycin (Invitrogen, UK).
Hepatocyte DNL
The rate of DNL was measured by the amount of uptake of 1-[14C]-acetate into
the lipid component of hepatocytes, as described previously [25]. After serum
starvation, hepatocytes were incubated for 12 hours in serum free media contain-
ing Exendin-4 (10 nM or 100 nM). 1-[14C]-acetic acid [0.12 lCi/L; Perkin Elmer)
with unlabeled sodium acetate [10 lM] was added to the treated serum-free
media for an additional 6 hours. After incubation cells were washed and scraped
into 250 ml of PBS (1). The lipid fraction was recovered in Folch solvent (chlo-
roform:methanol 2:1), the solvent was evaporated and the 14C radioactivity
retained in the cellular lipid was determined by scintillation counting and
expressed as disintegrations per minute (dpm)/per well.
Hepatocyte NEFA uptake and b-oxidation
The rate of NEFA uptake and b-oxidation was measured by the intracellular
accumulation of 9,10-[3H]-palmitate and the conversion of 9,10-[3H]-palmitate
(Perkin Elmer) to [3H] labeled-H2O, respectively; using a modification of the
method described previously (Supplementary Methods) [26].
Oil Red O staining and triglyceride assays
HuH7 cells were exposed to DMEM containing 0.5% NEFA–free BSA and fat loaded
with a mixture of 200 lM palmitic and 200 lM oleic acid (Sigma). After 12 hours,
cells were washed with PBS (1) and treated with 10 nM–100 nM exendin-4 for
12 hours. After further washing, cells were either fixed for Oil Red O staining
(Sigma) or lysed for triglyceride quantification (Biovision #K622-100), using man-
ufacturer’s instructions (Supplementary Methods).
Statistical analysis
Continuous clinical and laboratory non-parametric variables were reported as
median and interquartile range (IQR), unless stated. Area under the curve
(AUC) analysis was performed using the trapezoidal method for interstitial
glycerol release during the clamp. Baseline clinical and biochemical characteris-
tics were compared between treatment groups using unpaired Wilcoxon
signed-rank tests and Fisher exact tests for continuous and categorical variables,
respectively. For each treatment group, comparison of baseline vs. post-treatment
data was performed using paired Wilcoxon signed-rank tests. Unpaired
Mann-Whitney tests were used to compare delta change (post-treatment minus
baseline value for each subject) of variables in the placebo control vs. liraglutide.
The significance level was set at p <0.05.
The in vitro data were expressed as mean ± SE. For comparison of two
treatment arms, paired t tests were used. ANOVA with Dunnett’s post hoc
analysis was used for comparisons of multiple doses and/or treatments. All anal-
ysis was performed using the GraphPad Prism 6.0 software package (GraphPad
Software, Inc; California, US).Results
Study participants
Fourteen patients were randomised to receive either placebo or
liraglutide for 12-weeks. The two treatment groups were well
matched with regards to baseline demographic characteristics,
clinical, biochemical and clamp data (Table 1; Supplementary
Tables 2 and 3). There were no significant differences betweenJournal of Hepatology 201the placebo and liraglutide groups with respect to baseline NASH
disease activity (median NAS [25th, 75th centile]: 4 [3,5] vs. 5
[4,5], p >0.05) and the presence of advanced fibrosis, defined as
Kleiner F3-F4 (4 vs. 5 participants, p >0.99). There was no
significant difference in the number of participants with type 2
diabetes (3 vs. 4), impaired (1 vs. 2) and normal glucose tolerance
(3 vs. 1; p = 0.478).
Clinical variables
Liraglutide decreased weight (6.0 [7.0,5.0] kg; p <0.05), BMI
(1.9 [2.8,1.5] kg/m2; p = 0.01), and total fat mass (3.5
[4.1,1.8] kg; p <0.05) from baseline. In addition, waist circum-
ference decreased (8.0 [10.0,6.0] cm; p <0.05) as did abdom-
inal fat mass (1.6 [2.3,0.9] kg, p <0.05). In contrast, treatment
with placebo resulted in no baseline changes with respect to
anthropometric measures (Table 1). Glycemic control (HbA1c)
improved with liraglutide treatment (0.3 [1.2,0.1]%;
p <0.05). Direct comparisons (median change from baseline) of
the treatment effects of placebo and liraglutide are summarised
in Table 1.
Liraglutide improves liver biochemistry and markers of inflammation
Liraglutide improved liver enzymes from baseline, most notably
aspartate transaminase (AST) (64 [40,87] vs. 37 [23, 39] IU/L;
p <0.05) and alanine transaminase (ALT) (90 [36,137] vs. 36 [25,
74] IU/L; p <0.05). In contrast, no significant reductions were seen
in the placebo group (Table 1). In direct comparison of delta
changes from baseline, liraglutide significantly reduced AST,
ALT and gamma-glutamyl transpeptidase (GGT) compared to pla-
cebo. Liraglutide reduced fasting serum leptin (12.7 [10.4,22.8]
vs. 10.6 [8.39,13.5] ng/ml; p <0.05) and increased adiponectin
(4.47 [3.68,6.47] vs. 6.28 [4.24,8.75] lg/ml; p <0.05) from base-
line resulting in a significant reduction in the leptin-to-
adiponectin ratio (3.15 [2.11,4.24] vs. 1.55 [1.18,2.85] ng/lg;
p <0.05), implying improved adipose tissue function. Liraglutide
reduced the levels of pro-inflammatory markers including
CCL-2 (210 [203,238] vs. 203 [171,225] pg/ml; p <0.05) and
high-sensitivity C-reactive protein (1.55 [0.63,3.89] vs. 0.46
[0.25,1.53] lg/ml; p <0.05). In direct comparison to the placebo
group, circulating levels of adiponectin, leptin and CCL-2 were
significantly lower in patients after liraglutide treatment. No
significant reductions were seen in the placebo group (Table 2).Liraglutide improves systemic insulin sensitivity
Liraglutide reduced fasting serum glucose from baseline (5.48
[4.87,5.61] vs. 4.76 [4.65,4.83] mmol/L; p <0.05), whereas fasting
serum glucose increased in patients receiving placebo (4.51
[4.43,7.17] vs. 4.78 [4.63,8.99] mmol/L; p <0.05). Liraglutide
decreased fasting glucose from baseline compared to placebo
(median baseline change: 0.65 [0.91,0.17] vs. 0.28
[0.01,1.34] mmol/L; p <0.001). Liraglutide did not change fasting
insulin levels in comparison with baseline or with placebo
(Table 1).
Liraglutide improves hepatic insulin sensitivity
Liraglutide increased the ability of low-dose insulin to suppress
hepatic EGP (43.2 [47.4,41.1] vs. 51.7 [52.7,49.5]%;6 vol. 64 j 399–408 401
Table 1. Changes in metabolic and liver parameters in participants receiving liraglutide and placebo for 12 weeks.
Placebo (n = 7) Liraglutide (n = 7) p value **
Baseline Median change 
from
baseline
p value *
(12 wk vs.
baseline)
Baseline Median change 
from
baseline
p value *
(12 wk vs.
baseline)
Liraglutide
vs. placebo
Metabolic factors
BMI (kg/m2) 36.5
(29.3, 40.0)
+0.04
(-0.3, +0.7)
0.81 34.0
(30.7, 35.9)
-1.9
(-2.8, -1.5)
0.01 0.0006
Weight (kg) 101
(85.6, 119)
+0.3
(-1.0, +2.1)
0.48 108
(82.5, 115)
-6.0
(-7.0, -5.0)
0.016 0.0006
Waist circumference (cm) 118
(99.0, 127)
+2.0
(-3.0, +2.5)
0.78 116
(102, 121)
-8.0
(-10.0, -6.0)
0.031 0.004
Total fat mass (kg) 36.2
(28.0, 49.2)
-0.4
(-1.1, +1.3)
>0.99 33.9
(30.5, 36.7)
-3.5
(-4.1, -1.8)
0.016 0.007
Truncal fat mass (kg) 41.1
(30.8, 49.2)
-0.2
(-1.6, +0.6)
0.38 34.6
(32.3, 36.6)
-1.6
(-2.3, -0.9)
0.016 0.079
Systolic BP (mmHg) 136
(128, 146)
+5.5
(-5.5, +10.0)
0.59 128
(121, 133)
-0.5
(-10.0, -2.5)
0.57 0.40
HbA1c % 5.5
(5.3, 6.3)
+0.3
(-0.1, +1.4)
0.16 6.0
(5.6, 6.4)
-0.3
(-1.2, -0.1)
0.031 0.006
Serum glucose (mmol/L) 4.51
(4.43, 7.17)
+0.28
(+0.01, +1.34)
0.047 5.48
(4.87-5.61)
-0.65
(-0.91, -0.17)
0.016 0.006
Serum insulin (pmol/L) 133
(88.0, 220)
-3.30
(-13.5, +30.3)
0.57 98.0
(81.9-109)
+3.45
(-37.8, +19.8)
0.81 0.88
Total cholesterol (mmol/L) 4.50
(4.00, 5.06)
-0.1
(-0.5, +0.1)
0.17 4.30
(3.90, 5.30)
-0.8
(-1.2, -0.5)
0.016 0.004
HDL cholesterol (mmol/L) 1.15
(1.00, 1.38)
-0.2
(-0.2, -0.1)
0.016 1.12
(0.90, 1.30)
-0.1
(-0.2, -0.03)
0.031 0.17
LDL cholesterol (mmol/L) 3.01
(2.21, 3.65)
+0.05
(-0.2, +0.4)
0.81 2.58
(2.40, 3.86)
-0.7
(-0.8, -0.5)
0.016 0.004
Triglycerides (mmol/L) 1.68
(1.31, 2.12)
+0.3
(-0.04, +1.0)
0.38 1.58
(1.43, 1.73)
-0.1
(-0.3, +0.2)
0.38 0.097
TSH (µU/L) 2.80
(1.37, 4.06)
-0.18
(-0.38, +0.13)
0.47 2.14
(1.31, 2.41)
-0.42
(-0.53, +0.77)
0.69 0.52
Creatinine (µmol/L) 62.0
(57.0, 77.0)
0.0
(-6.0, +7.0)
0.63 71.0
(70.0, 89.0)
-7.0
(-13.0, -3.0)
0.031 0.023
Liver enzymes
AST (IU/L) 49.0
(34.0, 70.0)
+9.0
(-3.00, +15.0)
0.36 64.0
(40.0, 87.0)
-27.0
(-45.0, -3.0)
0.016 0.025
ALT (IU/L) 57.0
(20.0, 70.0)
-4.00
(-6.00, +16.0)
0.22 90.0
(36.0, 137)
-54.0
(-65.0, -18.0)
0.031 0.004
GGT (IU/L) 73.0
(55.0, 179)
-11.0
(-31.0, -4.0)
0.22 124
(69.0, 183)
-36.0
(-75.0, -25.0)
0.016 0.079
ALP (IU/L) 80.0
(56.0, 106)
-8.3
(-18.7, -2.0)
0.156 67.0
(57.0, 83.0)
-9.8
(-14.0, -7.0)
0.031 0.60
Values are median (25th, 75th centiles). All blood parameters were in the fasting state. ⁄p value, Wilcoxon pairs-signed-rank test. ⁄⁄p value, unpaired Mann-Whitney U test.
There was no significant in baseline parameters between the two treatment groups.
Research Articlep <0.05), consistent with improving hepatic insulin sensitivity,
whereas there was no significant change in the placebo group
(49.2 [51.0,47.5] vs. 51.9 [52.8,37.0]%; p = 0.94). The
median difference in change in hepatic EGP with low-dose insulin
was also greater with liraglutide than placebo (0.10
[0.4,0.03] vs. 0.12 [0.08, 0.47]%; p <0.05) (Fig. 1A).
Liraglutide did not alter muscle insulin sensitivity
Liraglutide did not change weight-adjusted Gd rates in the
low-dose (0.89 [0.61,0.97] vs. 0.76 [0.57,0.94] mg/kg/min;402 Journal of Hepatology 201p = 0.69) or high-dose insulin phases of the clamp (4.95
[2.49,6.50] vs. 3.28 [2.54,3.51] mg/kg/min; p = 0.38). Similarly,
patients treated with placebo had no differences in
weight-adjusted Gd rates from baseline (Fig. 1B).
Liraglutide improves whole body adipose insulin sensitivity and
lipolysis
Liraglutide significantly reduced circulating NEFA in the fasting
(595 [425,656] vs. 452 [397,491] lmol/L; p <0.05) and hyperinsu-
linemic states, consistent with decreased whole body lipolysis.6 vol. 64 j 399–408
Table 2. Effect of liraglutide and placebo on fasting serum adipocytokines and inflammatory markers.
Cytokine/inflammatory 
marker Placebo (n = 7) Liraglutide (n = 7) p value **
Median change p value *
(12-wk vs. baseline)
Median change p value *
(12-wk vs. baseline)
Liraglutide vs. placebo
Adiponectin (µg/ml) -0.22
(-1.67, +0.38)
0.58 +1.33
(+0.56, +1.86)
0.016 0.018
Leptin (ng/ml) +0.52
(-1.83, +0.76)
0.69 -3.16
(-3.56, -1.98)
0.016 0.026
Leptin:adiponectin ratio 
(ng/µg)
+0.045
(-1.48, +0.55)
0.79 -1.04
(-1.91, +0.85)
0.016 0.097
Resistin (ng/ml) -0.025
(-0.76, +0.48)
0.94 +0.59
(+0.46, +1.04)
0.016 0.073
TNFα (pg/ml) 0.00
(-0.12, -1.33)
0.81 -1.33
(-2.72, 0.00)
0.13 0.12
hs-CRP (mg/ml) -1.48
(-3.47, +2.29)
0.47 -0.45
(-1.23, -0.22)
0.016 0.78
IL-6 (pg/ml) +0.04
(-1.56, +1.95)
0.92 -0.78
(-1.17, 0.00)
0.16 0.55
CCL-2 (pg/ml) +19.2
(-8.3, +30.1)
0.16 -9.14
(-22.3, -6.29)
0.031 0.026
CCL-4 (pg/ml) -48.6
(-50.7, +8.91)
0.38 -40.4
(-63.6, +2.41)
0.11 0.60
CCL-5 (pg/ml) -3.20
(-7.08, +15.8)
0.99 +4.58
(-8.07, +13.2)
0.38 0.87
Adipocytokine profile performed on fasting serum at baseline and after 12-weeks treatment with either placebo or liraglutide. Values are median (25th, 75th centiles).
⁄p value, wilcoxon pairs-signed-rank test. ⁄⁄p value, unpaired Mann-Whitney U test.
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Fig. 2. Liraglutide significant reduces whole body lipolysis and adipose
insulin resistance. (A) Tukey box-and-whisker plots representing NEFA concen-
trations at the basal and hyperinsulinaemic phases of euglycaemic clamp.
Liraglutide reduced NEFA at every phase of the clamp compared to placebo. (B)
Tukey box-and-whisker plots representing the effect of liraglutide vs. placebo on
insulin concentration required to achieve ½ maximal suppression of circulating
NEFA (INS-½-max NEFA). ⁄p <0.05 treatment vs. baseline (using paired Wilcoxon
signed-rank tests). Unpaired Mann-Whitney tests were used to compare liraglu-
tide vs. placebo.
JOURNAL OF HEPATOLOGYSimilarly, there were no differences in the fasting (421 [397,628]
vs. 534 [466,636] lmol/L; p = 0.35) or hyperinsulinemic states in
placebo treated patients. Circulating NEFA concentrations
decreased with liraglutide vs. placebo treatment in the fasting
(95.8 [183,79.8] vs. +61.8 [122,164] lmol/L; p <0.05),
low-dose insulin (66.8 [115,34.5] vs. +1.05 [33.7,88.7]
lmol/L; p = 0.007) and high-dose insulin (15.1 [23.6,4.1] vs.
0.0 [5.52,16.1] lmol/L; p = 0.007) phases of the euglycaemicJournal of Hepatology 201clamps (Fig. 2A). In the fasting state, liraglutide significantly
reduced the Adipose-IR index (8.42 [5.02,9.88] vs. 6.26
[4.41,7.28] mmol/L.uU/L; p <0.05), consistent with decreased adi-
pose IR; there was no change in the placebo arm (8.03 [5.34,15.8]
vs. 10.2 [7.67,12.5] mmol/L.uU/L; p = 0.38). Similarly, liraglutide
significantly reduced INS-½-max NEFA, with no reported change6 vol. 64 j 399–408 403
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Research Articlewith placebo. Furthermore, liraglutide significantly reduced
INS-½-max NEFA as compared to placebo (24.9 [107,9.73]
vs. +54.8 [14.4,56.0) pmol/L; p <0.05), consistent with enhanced
anti-lipolytic action of insulin following liraglutide treatment
(Fig. 2B).
Liraglutide improves subcutaneous adipose insulin sensitivity and
lipolysis
Liraglutide reduced the rate of glycerol release from SAT in
response to both low-dose (454 [347,504] vs. 321 [245,418]
AUC.lmol/L.hr; p <0.05) and high-dose insulin (307 [214,360]
vs. 194 [106,221] AUC.lmol/L.hr; p <0.05), consistent with
increased abdominal SAT insulin sensitivity (Fig. 3A). Treatment
with placebo had no effect on the rate of glycerol release into
the interstitial fluid at either low-dose (352 155,437] vs. 348
[287,420] AUC.lmol/L.hr; p = 0.68) or high-dose insulin (226
[71.3,372] vs. 237 [133,409] AUC.lmol/L.hr; p = 0.11) (Fig. 3B).
Furthermore, liraglutide significantly reduced the rate of glycerol
release from SAT when compared to placebo (Fig. 3C). Despite
normalizing the rate of glycerol release from SAT to changes in
truncal fat mass (kg), the effect of liraglutide on abdominal SAT
insulin sensitivity remained; thereby implying that the effect
was independent of a tissue mass effect (Supplementary Fig. 2).
Liraglutide reduces hepatic DNL in vivo
The percentage contribution of hepatic DNL to total endogenous
palmitate synthesis did not significantly change from baseline
with either placebo (5.24 [4.42,6.90] vs. 6.85 [4.43,9.58]%;
p = 0.22) or liraglutide (4.87 [4.38,5.66] vs. 3.26 [2.58,4.85]%;
p = 0.15). However, liraglutide reduced hepatic DNL when com-
pared directly to placebo (median change: 1.26 [2.34,0.40]
vs. +1.30 [0.56,2.91]%; p <0.05) (Fig. 4A).
GLP-1 receptor (GLP-1R) analogues reduce hepatocyte steatosis
in vitro through a reduction in hepatic DNL
Supporting the in vivo observations, GLP-1 receptor analogues
(10 nM exendin-4) decreased 14C-acetate incorporation into
intracellular lipid in both HuH7 cells (49.4 ± 7.1% decrease vs.404 Journal of Hepatology 201control; p <0.05, n = 4) and primary human hepatocytes
(24.6 ± 2.8% decrease vs. control; p <0.01, n = 4) in a
concentration-dependent manner (100 nM exendin-4: HuH7,
70.5 ± 2.4%; primary hepatocytes, 30.7 ± 2.0% decrease vs. con-
trol; p <0.01 for both cell types) (Fig. 4B).
Exendin-4 (10 nM or 100 nM) had no effect on 3H-palmitate
uptake (NEFA uptake) when compared to untreated cells
(10 nM: 99.1 ± 5.7; 100 nM: 101.9 ± 8.6% of controls; p >0.05 for
both doses, n = 4) (Fig. 4C). As expected, insulin (5 nM) decreased
b-oxidation, however exendin-4 treatment (10 nM or 100 nM)
did not change rates of b-oxidation (10 nM: 96.5 ± 5.9; 100 nM:
106.2 ± 7.0% of controls; p >0.05 for both concentrations, n = 4)
(Fig. 4D).
100 nM exendin-4 treatment (12 h) decreased intracellular
triglyceride content, as demonstrated by a reduction in Oil Red
O staining (Fig. 5A) and formal triglyceride quantification
(10 nM exendin-4: 46.9 ± 2.4 vs. 26.5 ± 3.5 nmol/L/106 cells;
p = 0.075; 100 nM exendin-4: 46.9 ± 2.4 vs. 23.9 ± 2.2
nmol/L/106 cells; p <0.05) (Fig. 5B).Discussion
Therapies that protect the liver from the effects of lipotoxicity are
believed to be essential for preventing the progression of NASH to
end-stage disease [8]. Our experimental medicine study dissects
the mechanism of action of the GLP-1 analogue, liraglutide, in
patients with NASH. Liraglutide improved both hepatic and glo-
bal/localised adipose insulin sensitivity, thereby reducing the
amount of lipotoxic metabolites and pro-inflammatory mediators
in the circulation. In addition, liraglutide reduced hepatic DNL
in vivo, a key component of hepatic lipid accumulation in NASH.
Supporting this clinical observation, our in vitro isotope studies
indicated that GLP-1R analogues also have an anti-lipogenic
action on hepatocytes, which cannot be attributed to weight loss.
Liraglutide decreased fasting glucose, although changes in Gd
(during hyperinsulinaemia) did not change significantly, and this
is in agreement with the published literature that has shown
inconsistent actions of GLP-1 on skeletal muscle insulin action
[19,21,22,27]. These data would suggest that sites other than
skeletal muscle (namely liver and adipose tissue) are the key tar-
gets for the beneficial effects of liraglutide in this study.6 vol. 64 j 399–408
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JOURNAL OF HEPATOLOGYOur study has shown significant metabolic improvements in
the liver following treatment with liraglutide. We have previ-Journal of Hepatology 201ously shown that the suppression of hepatic EGP by insulin is
blunted in patients with NASH [24] and data from our current
study indicate that liraglutide is able to restore hepatic insulin
sensitivity in patients with NASH. It is likely that this is the major
contributor to the improvement in fasting glucose levels. These
effects on hepatic insulin sensitivity are supported by GLP-1 stud-
ies in patients with [20,28] and without [19,21] type 2 diabetes,
albeit that the duration of treatment in these studies was shorter
and the underlying status of liver disease was unknown. The
mechanisms by which GLP-1 induce hepatic insulin sensitivity
are not clear, with earlier studies attributing it to GLP-1’s inhibi-
tory effect on glucagon and subsequent decrease in hepatic
glycogenolysis and gluconeogenesis [29]. In contrast, recent stud-
ies in rodents and humans have shown that the effect is likely
independent of endogenous pancreatic hormones [21,27].
Hepatic DNL is a major contributor to lipid accumulation in
the context of NAFLD [6]. We have provided the first in vivo evi-
dence that GLP-1 based therapy can decrease DNL in patients
with biopsy-proven NASH. Although the basal percentage contri-
bution of hepatic DNL to total hepatic lipid content is lower than
previously reported (4.9%) [6,7], we still observed a significant
reduction in the percentage of hepatic DNL with liraglutide vs.
placebo. Supporting our clinical observations in patients with
NASH, we found that GLP-1R agonist (exendin-4) significantly
reduced hepatic DNL (as measured by the incorporation of
14C-acetate into cellular lipid) in both hepatoma cell lines and
primary cultures of human hepatocytes. Our data are supported
by weight neutral studies in rodents [12,30] and the reduced
gene expression of key enzymes involved in hepatocyte DNL
including fatty acid synthetase, acetyl-CoA carboxylase 1, sterol
regulatory element-binding protein 1 after GLP-1 treatment in
culture [10,14,31]. Collectively, these data highlight the possibil-
ity that the effects of GLP-1R agonists on DNL can occur in the
absence of weight loss. However, whether these effects are initi-
ated directly via the transmembrane GLP-1R remains uncertain;
largely as a result of discrepant reports of receptor expression
on human hepatocytes [32].
Gene expression studies have highlighted the potential of
GLP-1 to drive lipid oxidation in vitro [10,14,31], however, we6 vol. 64 j 399–408 405
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did not observe a functional effect of GLP-1R agonism on
b-oxidation (or fatty acid uptake) in hepatocytes using
radio-labeled tracers. This implies that the majority of the
anti-steatotic effect of GLP-1R agonism on hepatocytes is via
DNL, rather than b-oxidation or NEFA uptake. In our cell cultures
systems, GLP-1R agonism was able to decrease total lipid
accumulation in the absence of insulin and it is possible that this
may protect the hepatocyte from oxidative (endoplasmic reticu-
lum) stress and subsequent cellular death in vitro [11] in a similar
manner to observations made in pancreatic b-cells.
The beneficial effects of GLP-1 therapy are not confined to the
liver and in our study we observed significant improvements in
markers of adipose tissue function. The delivery of adipose tissue
derived NEFA is the major factor driving lipid accumulation in
NASH [6]. Furthermore, there is a growing body of evidence to
suggest that adipose IR and subsequent excess release of NEFA
into the circulation are linked with the onset of peripheral and
hepatic IR [33], and progressive liver injury [4]. Therefore, treat-
ments that are able to target adipose tissue dysfunction have the
potential to impact upon the progression of NASH and its
associated cardiovascular risk.
In the current study, liraglutide decreased circulating NEFA
levels in the fasting state and enhanced insulin-mediated sup-
pression of lipolysis. Rodent studies have reported similar effects
on fasting NEFA levels [15,17], but have not examined the impact
upon insulin action to suppress lipolysis. Zander et al. have
shown that 6 weeks of continuous subcutaneous GLP-1 infusion
in patients with type 2 diabetes resulted in significant reductions
in fasting and post-prandial NEFA levels [20]. In contrast, Seghieri
and colleagues found no effect of GLP-1 on lipolysis, as deter-
mined by free fatty acid concentrations and tracer isotope studies
[27]. This discrepancy may be explained by: duration of the treat-
ment (i.e. 8 hours vs. 12-weeks therapy in our study); administra-
tion of treatment (i.e. intravenous native GLP-1 vs. subcutaneous
GLP-1 analogue in our study); and the fact that the Segieri et al.
utilised healthy volunteers, as opposed to patients with biopsy-
confirmed NASH; and the reliance on global lipolysis readouts
rather than localised abdominal adipose (SAT) tissue sampling
(i.e. microdialysis). In rodent pre-adipocytes, GLP-1 augments
insulin signaling through increased phosphorylation of IRS-1
and Akt, which in turn leads to enhanced glucose uptake
[34,35]. A direct action of GLP-1 to regulate lipolysis in the
absence of insulin has not been a consistent in vitro finding and
may reflect variations in dosage and culture conditions [35–37].
Similarly to hepatocytes, the presence of the GLP-1R in human
adipocytes remains controversial. Interestingly, Vendell and col-
leagues reported that GLP-1R expression (mRNA, protein) is
greatest in adipocytes isolated from patients with morbid obesity
and in particular, IR [35]. The adipose tissue interstitial fluid
analysis that we have performed would further endorse the con-
cept of adipose tissue insulin sensitization by GLP-1 in a tissue
where dysfunction is believed to be an important contributor to
the pathogenesis and progression of NASH [4,5,24,38]. Whilst
we did not measure adipose tissue blood flow, previous studies
have shown that it is not altered by GLP-1 and this would there-
fore not compromise out interpretation of our data, which mir-
rors changes in circulating NEFA levels [39]. Through
sensitization of abdominal SAT to insulin, it is likely that liraglu-
tide can increase its buffering capacity in response to external
insults, for example as seen in calorific excess. As a result, the
liver and other metabolically active organs may be protected406 Journal of Hepatology 201from the overspill of lipotoxic metabolites into the systemic
circulation.
Changes in the circulating pro-inflammatory milieu associ-
ated with NASH also suggest improved adipose tissue function
following GLP-1 analogue therapy. Although adipose tissue biop-
sies were not performed as part of our study protocol, reductions
in adipose tissue inflammation have been observed in rodents
treated with DPP-IV inhibitor that increase endogenous GLP-1
levels [12]. Notably, we demonstrated increased levels of circu-
lating adiponectin following liraglutide treatment, which were
accompanied by corresponding reductions in circulating leptin
levels. Furthermore, the leptin-to-adiponectin ratio was reduced
to levels similar to those found in healthy volunteers [24]. Impor-
tantly, liraglutide has recently been shown to increase the
expression and secretion of adiponectin from adipose tissue in
a rodent model of NASH [18]. Furthermore, increases in circulat-
ing adiponectin, either via direct supplementation or secondary
to other therapies have been implicated in the resolution of lipo-
toxic liver injury and fibrosis in humans [40]. Although our data
do not allow us to be categorical, it is highly likely that the ben-
eficial effects of liraglutide on adipose tissue metabolism (along-
side the direct actions on the liver) will contribute to improved
hepatic metabolic function and potential improvement in NASH.
The current study has recognised limitations. Firstly, even
though clamp techniques are the recognised gold-standard for
assessment of tissue-specific insulin sensitivity, the small sample
size highlights the practical challenges of incorporating optional
paired studies in a randomised-controlled clinical trial. Although
the sample size limits statistical sub-group analysis (i.e. stage of
fibrosis, diabetes status), the fact that 5/7 (71%) patients in the
liraglutide arm had advanced fibrosis (F3/F4) highlights that
improvements seen in adipose dysfunction, lipogenesis and insu-
lin sensitivity are not limited to earlier stages of fibrosis. Indeed,
larger powered studies are now warranted to validate our find-
ings and investigate which phenotypic variables (i.e. fibrosis
stage, presence of diabetes) influence the metabolic response to
liraglutide. Secondly, is the confounding issue of weight loss in
our study; patients lost approximately 6% of their initial starting
body weight in the liraglutide treated group. This has made
mechanistic interpretation of all data from studies that have used
GLP-1 based therapy problematic. It is plausible that our observa-
tions could be explained by significant weight loss, however,
rodent (weight neutral) studies, together with our in vitro data
suggest that there are actions of GLP-1, which are not entirely
dependent on weight loss. Throughout our in vitro studies,
exendin-4 (exenatide) was selected over liraglutide as the thera-
peutic of choice, due to its commercial availability (in 2009) and
stability in cell culture. Therefore future studies would usefully
validate our findings with liraglutide in cell culture.
When this study was designed liraglutide was only available
at the 1.8 mg dose, and since then the higher dose of 3.0 mg
has been approved for weight management in the presence or
absence of diabetes. It is plausible that the higher dose of liraglu-
tide could provide greater efficacy in the setting of NASH and
multi-organ IR, however this requires confirmation in future
studies and should be weighed against the possibility of greater
side-effects.
In summary, the data from this experimental study demon-
strate the possible mechanisms by which liraglutide mediates
its beneficial clinical and metabolic effects in patients with NASH.
Specifically, liraglutide enhanced hepatic insulin sensitivity and6 vol. 64 j 399–408
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decreased lipogenesis, which in part was not dependent on
weight loss. In parallel, liraglutide increased adipose insulin
sensitivity, thereby reducing the lipotoxic capabilities of
dysfunctional fat tissue in NASH. This class of agent therefore
has the potential to offer a novel therapeutic approach to the
treatment of NASH and its CVD risk profile.Conflict of interest
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